The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma

• Published in: Cell death & disease Vol. 11; no. 10; p. 902
• Main Authors: Zhang, Zhongqiang, Tan, Xiao, Luo, Jing, Yao, Hongliang, Si, Zhongzhou, Tong, Jing-Shan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23-10-2020; Springer Nature B.V
• Subjects: 1-Phosphatidylinositol 3-kinase; 13/2; 13/31; 13/51; 13/89; 13/95; 38/77; 631/67/1059/2326; 64/60; 692/699/67/1504/1610; AKT protein; Animals; Antibodies; Antineoplastic Agents - pharmacology; Biochemistry; Biomedical and Life Sciences; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - pathology; Cell Biology; Cell Culture; Cell Line, Tumor; Cell Movement - genetics; Cell Proliferation - drug effects; Cell Proliferation - genetics; Chemotherapy; Cholesterol; Drug resistance; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - genetics; Gene Expression Regulation, Neoplastic - drug effects; Gene Expression Regulation, Neoplastic - genetics; Glucose metabolism; Glycolysis; Hepatocellular carcinoma; Humans; Immunology; Life Sciences; Liver cancer; Liver Neoplasms - genetics; Liver Neoplasms - pathology; Mice; MicroRNAs - genetics; Signal Transduction - drug effects; Sorafenib - metabolism; Sorafenib - pharmacology; Targeted cancer therapy; Tumors; Western blotting; Xenografts
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-020-03123-3

HCC (hepatocellular carcinoma) is a major health threat for the Chinese population and has poor prognosis because of strong resistance to chemotherapy in patients. For instance, a considerable challenge for the treatment of HCC is sorafenib resistance. The aberrant glucose metabolism in cancer cells aerobic glycolysis is associated with resistance to chemotherapeutic agents. Drug-resistance cells and tumors were exposed to sorafenib to establish sorafenib-resistance cell lines and tumors. Western blotting and real-time PCR or IHC staining were used to analyze the level of CLCF1 in the sorafenib resistance cell lines or tumors. The aerobic glycolysis was analyzed by ECAR assay. The mechanism mediating the high expression of CLCF1 in sorafenib-resistant cells and its relationships with miR-130-5p was determined by bioinformatic analysis, dual luciferase reporter assays, real-time PCR, and western blotting. The in vivo effect was evaluated by xenografted with nude mice. The relation of CLCF1 and miR-30a-5p was determined in patients’ samples. In this study, we report the relationship between sorafenib resistance and increased glycolysis in HCC cells. We also show the vital role of CLCF1 in promoting glycolysis by activating PI3K/AKT signaling and its downstream genes, thus participating in glycolysis in sorafenib-resistant HCC cells. Furthermore, we also show that miR-30a-5p directly targets CLCF1 and that sorafenib-mediated suppression of miR-30a-5p results in the upregulation of CLCF1 in HCC cells resistant to sorafenib. We also found that when a cholesterol modified agomiR-30a-5p was delivered systemically to mice harboring sorafenib-resistant HCC tumors, tumor growth decreased significantly. There is an uncharacterized mechanism of biochemical resistance to hormone therapies orchestrated by the miR-30a-5p/CLCF1 axis to mediate sorafenib resistance and aerobic glycolysis in HCC. Therefore, this study indicates that targeting the miR-30a-5p/CLCF1 axis may hold promise for therapeutic intervention in HCC sorafenib resistance patients.